Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer

    Clinical and translational medicine, 2020.

    Cited by: 0|Bibtex|Views4|Links
    WOS
    Keywords:
    ApatinibEGFR-TKIsGefitinibNSCLCantiangiogenic therapy

    Abstract:

    Clinicaltrials.gov, NCT02824458, date of registration June 23, 2016.

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments